Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2003
11/27/2003WO2003097028A1 Use of edg receptor binding agents in cancer
11/27/2003WO2003097027A1 OIL-IN-WATER EMULSION OF l-MENTHOL
11/27/2003WO2003097026A1 Smooth muscle peristole inhibitor
11/27/2003WO2003097025A2 A process for preparing pharmaceutical compositions containing 4-aminoquinolines compounds for treatment of inflammatory disorders of the eye and compositions resulting therefrom
11/27/2003WO2003097024A1 Methods for the prevention and/or the treatment of neurological disorders
11/27/2003WO2003097023A1 The use of the inhibitor transmitter of ϝ-aminobutyric acid (gaba) in the manufacture of analgesic
11/27/2003WO2003097022A1 Matrix type patch containing bronchodilators
11/27/2003WO2003097021A2 Use of transdermal topical systems for the prevention and treatment of primary dysmenorrhea
11/27/2003WO2003097020A1 Transdermal delivery system with two superimposed adhesive layers having different affinities to the active substance comprised
11/27/2003WO2003097015A1 Short chain polymer for enhancing the bioadhesiveness of polymers on mucosal membrane
11/27/2003WO2003097010A1 Medicinal preparation in a colloid for topical application in the therapy and prophylaxis of states of pain and itching
11/27/2003WO2003097008A2 Transdermal delivery device for the administration of fentanyl
11/27/2003WO2003097001A1 Methods and compositions employing a dialkyl amide
11/27/2003WO2003096999A1 Improvements in or relating to oral chlorhexidine formulations
11/27/2003WO2003096997A1 Reduction of hair growth
11/27/2003WO2003096992A2 Treatment of cancer with mefloquire
11/27/2003WO2003096991A2 Amelioration of the development of cataracts and other opthalmic diseases
11/27/2003WO2003096990A2 Protein cages for the delivery of medical imaging and therapy
11/27/2003WO2003096989A2 Anti tubercular drug: compositions and methods
11/27/2003WO2003096987A2 Methods of use and compositions for the diagnosis and treatment of infectious disease
11/27/2003WO2003096984A2 Drug therapy for celiac sprue
11/27/2003WO2003096983A2 Method of treating dyslipidemic disorders
11/27/2003WO2003096982A2 Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/27/2003WO2003096980A2 Bicyclic modulators of androgen receptor function
11/27/2003WO2003096979A2 Drug therapy for celiac sprue
11/27/2003WO2003096975A2 Pharmaceutical compositions and methods of using c-21 modified epothilone derivatives
11/27/2003WO2003096973A2 A direct cellular energy delivery system
11/27/2003WO2003096970A2 Methods and compositions for treating t cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency
11/27/2003WO2003096968A2 Oral osmotic controlled drug delivery system
11/27/2003WO2003096965A2 Use of quinoline derivatives with anti-integrase effect and applications thereof
11/27/2003WO2003096944A1 Methods and formulations for the delivery of pharmacologically active agents
11/27/2003WO2003096877A2 Prevention and treatment of streptococcal and staphylococcal infection
11/27/2003WO2003096874A2 Coated sustained release tablets of a hygroscopic compound for once-a-day therapy
11/27/2003WO2003096808A1 Prevention or treatment of abnormal lipoprotein, cholestasis and atherosclerosis
11/27/2003WO2003096782A2 Process for preparing maytansinol
11/27/2003WO2003084464A3 Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them
11/27/2003WO2003080638A9 Antisense iap nucleobase oligomers and uses thereof
11/27/2003WO2003075841A3 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
11/27/2003WO2003074508B1 Compounds and methods of treating cell proliferative diseases
11/27/2003WO2003073997A3 Treatment of septic shock
11/27/2003WO2003073981A3 Novel of cytokine inhibitors
11/27/2003WO2003070315A3 Temperature control system for cutaneous photodynamic therapy
11/27/2003WO2003070157A3 Vitamin d upregulated protein 1 (vdup-1) methods and uses thereof
11/27/2003WO2003069302A3 Alpha-substituted arylalkyl phosphonate derivatives
11/27/2003WO2003067209A3 Ligands to enhance cellular uptake of biomolecules
11/27/2003WO2003066594A3 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6
11/27/2003WO2003065983A3 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
11/27/2003WO2003063876A3 Methods of treating patients suffering from movement disorders
11/27/2003WO2003061702A9 Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunsuppressor and anti-inflammatory agent
11/27/2003WO2003061636A3 Dna dosage forms
11/27/2003WO2003059881A3 Dna minor groove binding compounds
11/27/2003WO2003059382A3 Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression
11/27/2003WO2003059378A3 Combined use of a glp-1 compound and another drug for treating dyslipidemia
11/27/2003WO2003059271A3 Treatment involving peroxisome proliferator-activated receptor-gamma agonist and cyclooxygenase-2 selective inhibitors
11/27/2003WO2003059249A3 Nivalenol as specific inhibitor to transcriptional factor c-maf and pharmaceutical compositions comprising the same
11/27/2003WO2003056899A3 Nitric oxide donors for treatment of disease and injury
11/27/2003WO2003053354A3 Fused cyclic modulators of nuclear hormone receptor function
11/27/2003WO2003053336A3 Methods for the treatment of peripheral neural and vascular ailments
11/27/2003WO2003051383A3 Use of hmgb proteins and nucleic acids that code therefor
11/27/2003WO2003047417A3 Ep4 receptor agonist, compositions and methods thereof
11/27/2003WO2003042344A3 Apo2 ligand/trail formulations
11/27/2003WO2003041651A3 Allatoin-containing skin cream
11/27/2003WO2003040119A8 Angiogenesis inhibitors
11/27/2003WO2003039468B1 Antimnemonic therapy for hypermemory syndromes
11/27/2003WO2003039446A3 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
11/27/2003WO2003037338A3 Modulators of the cholesterol biosynthetic pathway
11/27/2003WO2003037331A8 Use of tetramisole and its derivatives against spore producing microorganisms
11/27/2003WO2003034275A3 Chimeric glycosylphosphatidylinositol containing peptides
11/27/2003WO2003032965A3 Use of ace inhibitors for reducing type 2 diabetes in high risk patients
11/27/2003WO2003032964A3 Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
11/27/2003WO2003030832A3 Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
11/27/2003WO2003030824A3 Methods and compositions for treating dermal lesions
11/27/2003WO2003028656A3 Adjuvant compositions
11/27/2003WO2003028649A3 Novel composition of carvedilol
11/27/2003WO2003022852A3 Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
11/27/2003WO2003022209A3 Crystalline forms of valacyclovir hydrochloride
11/27/2003WO2003020759A3 A caspase- 8 binding protein, its preparation and use
11/27/2003WO2003020222A3 PYRROLO[2,3-d]PYRIMIDINES FOR INHIBITING RNA-DEPENDENT RNA VIRAL POLYMERASE
11/27/2003WO2003020221A3 Method of treating cancerous disease
11/27/2003WO2003018636A3 Chimaeric peptides of insulin, their compositions and use in treating diabetes
11/27/2003WO2003018038A3 Composition for the treatment of varicose veins
11/27/2003WO2003015717A3 Tyrosine kinase inhibitors
11/27/2003WO2003015713A3 Treatment of glial tumors with glutamate antagonists
11/27/2003WO2003014102B1 Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors
11/27/2003WO2003014064A8 Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
11/27/2003WO2003011846A3 Process for the preparation of 5-substituted isobenzofurans
11/27/2003WO2003011207A3 Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine
11/27/2003WO2003009850A1 Substituted piperazines as modulators of the melanocortin receptor
11/27/2003WO2003009836A3 New uses for 2-amino-2-propane-1,3-diols
11/27/2003WO2003008429A3 Solvent-free anthracycline derivatives
11/27/2003WO2003007888A3 Fat accumulation-modulating compounds
11/27/2003WO2003007802A3 Pharmaceutical combinations of oxycodone and naloxone
11/27/2003WO2003006611A3 GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE
11/27/2003WO2003006425A3 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
11/27/2003WO2003005971A3 Tetracycline compounds having target therapeutic activities
11/27/2003WO2003003977A3 Compositions and methods for the treatment of body weight disorders, including obesity
11/27/2003WO2002100813A3 Modulators of peroxisome proliferator activated receptors
11/27/2003WO2002100388A3 Cyclopentane heptan (ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
11/27/2003WO2002099059A3 U5-200KDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
11/27/2003WO2002097075B1 Capping enzyme of flavivirus and utilization of this protein in a process to test drugs with antiviral properties
1 ... 5260 5261 5262 5263 5264 5265 5266 5267 5268 5269 5270 5271 5272 5273 5274 5275 5276 5277 5278 5279 5280 ... 7860